Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information.

Harbour BioMed is setting sail as the Solstice begins, riding the waves of biobucks potential that could reach heights up to $1.1 billion. | Harbour BioMed is setting sail as the Solstice begins, ...

Management will participate in a live fireside chat at 9:50am ET on Tuesday, March 3 rd and will also host one-on-one meetings with investors. The event will be accessible to investors and interested ...

Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...

Deal involving an antibody asset 'goes beyond a traditional licensing transaction', founder and CEO says China's Harbour BioMed has struck a deal worth more than US$1.2 billion with a clinical-stage ...

Orchestra BioMed’s hypertension treatment is the latest medical device to earn the FDA’s breakthrough designation. The device is an atrio-ventricular interval modulation therapy, meaning it uses a ...

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation ...

BioMed Realty Trust continues to push the life sciences conversion wave in Boston, quietly taking over two prominent development sites. The Blackstone-backed life sciences investor has entered a ...

BioMed Realty, the largest private operator of real estate for the life science and technology industries, today announced that its Gateway of Pacific campus in South San Francisco has been named a ...

SAN DIEGO--(BUSINESS WIRE)--BioMed Realty, a Blackstone portfolio company and leading provider of real estate solutions to the life science and technology industries, announced today that John Lee has ...